Qing Zhou

1.5k total citations
62 papers, 1.1k citations indexed

About

Qing Zhou is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Qing Zhou has authored 62 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 14 papers in Molecular Biology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Qing Zhou's work include Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Colorectal Cancer Treatments and Studies (5 papers). Qing Zhou is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Colorectal Cancer Treatments and Studies (5 papers). Qing Zhou collaborates with scholars based in China, United States and Canada. Qing Zhou's co-authors include Ann T. Farrell, Nitin Mehrotra, Robert C. Kane, Susan Kirshner, Minjiang Chen, Albert Deisseroth, Ping Zhao, Haw-Jyh Chiu, Mengzhao Wang and Donna Przepiorka and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Qing Zhou

56 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qing Zhou China 19 487 350 241 203 150 62 1.1k
Mohammad Hossein Kazemi Iran 14 398 0.8× 484 1.4× 287 1.2× 156 0.8× 240 1.6× 38 1.2k
Zhaoqin Huang China 19 691 1.4× 291 0.8× 273 1.1× 358 1.8× 136 0.9× 52 1.3k
Lorrin Yee United States 17 514 1.1× 446 1.3× 217 0.9× 128 0.6× 101 0.7× 37 1.0k
Ran Zhong China 20 501 1.0× 520 1.5× 243 1.0× 360 1.8× 318 2.1× 68 1.4k
Sander Bins Netherlands 17 688 1.4× 376 1.1× 150 0.6× 324 1.6× 117 0.8× 59 1.2k
Hong Zhu China 18 437 0.9× 371 1.1× 151 0.6× 324 1.6× 169 1.1× 62 1.3k
Shanthini Mary Crusz United Kingdom 7 504 1.0× 331 0.9× 253 1.0× 161 0.8× 224 1.5× 16 1.1k
Izumi Nagatomo Japan 18 535 1.1× 425 1.2× 120 0.5× 474 2.3× 209 1.4× 75 1.3k
Siu W. Lam Netherlands 12 252 0.5× 251 0.7× 150 0.6× 102 0.5× 128 0.9× 19 753
N. Lynn Henry United States 13 704 1.4× 302 0.9× 185 0.8× 147 0.7× 289 1.9× 43 1.1k

Countries citing papers authored by Qing Zhou

Since Specialization
Citations

This map shows the geographic impact of Qing Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qing Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qing Zhou more than expected).

Fields of papers citing papers by Qing Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qing Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qing Zhou. The network helps show where Qing Zhou may publish in the future.

Co-authorship network of co-authors of Qing Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Qing Zhou. A scholar is included among the top collaborators of Qing Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qing Zhou. Qing Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Dandan, et al.. (2025). A YOLO-Based Model for Detecting Stored-Grain Insects on Surface of Grain Bulks. Insects. 16(2). 210–210. 2 indexed citations
2.
Zhou, Qing, et al.. (2024). Board reforms and firm employment: Worldwide evidence. Journal of Banking & Finance. 171. 107379–107379. 2 indexed citations
3.
Xu, Jiayu, Yuhua Lei, Zhengqing Hu, et al.. (2024). Correlation between abnormal microvascular perfusion and quantitative flow ratio after primary PCI in patients with STEMI. International Journal of Cardiology. 422. 132949–132949.
4.
Zhou, Qing, Jie Yang, Wenyao Wang, et al.. (2023). The impact of the stress hyperglycemia ratio on mortality and rehospitalization rate in patients with acute decompensated heart failure and diabetes. Cardiovascular Diabetology. 22(1). 189–189. 41 indexed citations
5.
Cheng, Ying, Qing Zhou, Baohui Han, et al.. (2023). NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer. Lung Cancer. 178. 87–95. 6 indexed citations
6.
Zhong, Wei, Yalan Bi, Xiaoyan Liu, et al.. (2023). Molecular Subtypes and Prognostic Models for Predicting Prognosisof Lung Adenocarcinoma based on MiRNA-related Genes. Current Medicinal Chemistry. 31(34). 5620–5637.
7.
Klein, Karen O., et al.. (2023). Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study. Journal of the Endocrine Society. 7(7). bvad071–bvad071. 3 indexed citations
8.
Li, Shenglin, et al.. (2023). Role of iodine density value on dual-energy CT for detection of high tumor cell proportion region in lung cancer during CT-guided transthoracic biopsy. European Journal of Radiology. 160. 110689–110689. 3 indexed citations
9.
Wang, Fen, et al.. (2022). Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer. SHILAP Revista de lepidopterología. 2(4). 243–262. 15 indexed citations
10.
Li, Zhenxiang, Qing Zhou, Qi Wang, Haiyong Wang, & Weiming Yue. (2022). EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers. BMC Pulmonary Medicine. 22(1). 356–356. 1 indexed citations
11.
Chen, Yong, et al.. (2021). The role of B7-H3 in tumors and its potential in clinical application. International Immunopharmacology. 101(Pt B). 108153–108153. 37 indexed citations
12.
Bossuyt, Peter, Marc Ferrante, Filip Baert, et al.. (2021). OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. Journal of Crohn s and Colitis. 15(Supplement_1). S033–S034. 4 indexed citations
13.
Shu, Mengjun, Hongbin Yan, Yan Wu, et al.. (2020). A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo. Scientific Reports. 10(1). 2986–2986. 20 indexed citations
14.
Wang, Junhua, et al.. (2018). Design of a See-through Off-Axis Head-Mounted-Display Optical System with an Ellipsoidal Surface. Current Optics and Photonics. 2(3). 280–285. 1 indexed citations
15.
Wang, Dan, et al.. (2017). Surgical Repair of Rectovaginal Fistula Using the Modified Martius Procedure: A Step-by-Step Guide. Journal of Minimally Invasive Gynecology. 25(4). 573–575. 6 indexed citations
16.
Przepiorka, Donna, Chia‐Wen Ko, Albert Deisseroth, et al.. (2015). FDA Approval: Blinatumomab. Clinical Cancer Research. 21(18). 4035–4039. 261 indexed citations
17.
Lang, Liwei, Xiaoyu Liu, Yan Li, et al.. (2014). A Synthetic Manassantin A Derivative Inhibits Hypoxia-Inducible Factor 1 and Tumor Growth. PLoS ONE. 9(6). e99584–e99584. 19 indexed citations
18.
Wei, Rui, Yingjin Zhang, Liangfang Shen, et al.. (2011). Comparative proteomic and radiobiological analyses in human lung adenocarcinoma cells. Molecular and Cellular Biochemistry. 359(1-2). 151–159. 25 indexed citations
19.
Wang, Zheng, Yi‐Long Wu, Julie L. Yang, et al.. (2011). EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR.. Journal of Clinical Oncology. 29(15_suppl). e18072–e18072. 1 indexed citations
20.
Wang, Zhen, et al.. (2008). EGFR/KRAS Mutations and Gefitinib Therapy in Chinese NSCLC Patients. Onkologie. 31(4). 174–178. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mohammad Hossein Kazemi Breakdown of academic impact, for papers by Zhaoqin Huang Breakdown of academic impact, for papers by Lorrin Yee Breakdown of academic impact, for papers by Ran Zhong Breakdown of academic impact, for papers by Sander Bins Breakdown of academic impact, for papers by Hong Zhu Breakdown of academic impact, for papers by Shanthini Mary Crusz Breakdown of academic impact, for papers by Izumi Nagatomo Breakdown of academic impact, for papers by Siu W. Lam Breakdown of academic impact, for papers by N. Lynn Henry
Rankless by CCL
2026